The $203 million PRV sale provides a significant cash runway extension without dilution. Monitor the HSR waiting period expiration for closing timeline — the deal is structured as a straightforward asset sale with no ongoing milestones, so the full cash impact is a one-time event. The PRV monetization also removes a potential overhang of uncertainty around voucher value.
Price Chart
Executive Summary
Ultragenyx entered into an asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million in cash, awarded by the FDA on September 17, 2026 upon approval of FAYUVITM (UX111) for MPS IIIA. The transaction is subject to HSR antitrust clearance and customary closing conditions, providing a non-dilutive cash infusion.
Key Financial Metrics
Key Facts
- Ultragenyx entered into an asset purchase agreement on October 8, 2026 to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million in cash.
- The PRV was awarded by the FDA on September 17, 2026 upon approval of FAYUVITM (rebisufligene etisparvovec-hopf), also known as UX111, for MPS IIIA (Sanfilippo syndrome Type A).
- Closing is subject to expiration or termination of the HSR Act waiting period and other customary conditions.
- The full PRV Asset Purchase Agreement will be filed with the 2026 Form 10-K.
Financial Impact
Ultragenyx will receive $203 million in cash upon closing, a material non-dilutive capital infusion for a biotech with a single approved product.
Risk Factors
- HSR antitrust review could delay or block the transaction, though PRV sales are routine and rarely challenged.
- The buyer is not disclosed — counterparty risk exists if the buyer fails to secure financing or closes.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-421079 |
| Document: 0001193125-26-421079-index.html | 0001193125-26-421079 |
| Document: 0001193125-26-421079.txt | 0001193125-26-421079 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | SC 13G | $15.92 | awaiting T+5 | — | $16.08 (+1.01%) |
Oct 19, 2026 8d ago | 8-K | $15.07 $16.08 | ▲ +6.70% | ▲ +6.85% | $16.08 (+6.70%) |
Oct 14, 2026 13d ago | 8-K | $14.90 $15.92 | ▲ +6.85% | ▲ +6.39% | $16.08 (+7.92%) |
Oct 7, 2026 20d ago | 8-K | $14.89 $14.90 | ▲ +0.07% | ▲ +1.05% | $16.08 (+7.99%) |
Sep 17, 2026 5w ago | Press Release | $14.50 $14.77 | ▲ +1.86% | ▲ +1.01% | $16.08 (+10.90%) |
Sep 2, 2026 7w ago | 8-K | $14.85 $14.30 | ▲ +3.70% | ▲ +2.56% | $16.08 (−8.28%) |
Sep 1, 2026 8w ago | Press Release | $26.53 $14.40 | ▼ −45.72% | ▼ −44.76% | $16.08 (−39.39%) |
Aug 11, 2026 11w ago | 8-K | $26.80 $25.49 | ▼ −4.89% | ▼ −4.48% | $16.08 (−40.00%) |
Aug 4, 2026 12w ago | 8-K | $24.93 $26.86 | ▲ +7.74% | ▲ +7.39% | $16.08 (−35.50%) |
Aug 4, 2026 12w ago | Insider Cluster | $25.81 $26.96 | ▲ +4.46% | ▲ +4.56% | $16.08 (−37.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers